Breaking Barriers: Donovan Decker’s Journey in Gene Therapy and Advocacy for LGMD

Donovan Decker, recipient of the 2025 MDA Legacy Award for Community Impact and Research, shared his powerful journey as a patient advocate and gene therapy pioneer, shedding light on the challenges and progress in LGMD.:

Source: Neurology Read More

Previous PostCritical Lessons From Emergence of Enzyme Replacement Therapies in Pompe Disease: Priya Kishnani, MD
Next PostImmunovant Reports Positive Phase 3 and Phase 2b Results for Batoclimab in Myasthenia Gravis and CIDP

Breaking Barriers: Donovan Decker’s Journey in Gene Therapy and Advocacy for LGMD

Previous PostCritical Lessons From Emergence of Enzyme Replacement Therapies in Pompe Disease: Priya Kishnani, MD

Next PostImmunovant Reports Positive Phase 3 and Phase 2b Results for Batoclimab in Myasthenia Gravis and CIDP

Related Posts

<![CDATA[TEMPO-4 Extension Analysis: Tavapadon Shows Levodopa-Sparing Potential in Parkinson Disease]]>

<![CDATA[Telitacicept Moves Forward in Global Phase 3 Study for Generalized Myasthenia Gravis]]>

<![CDATA[Once-Daily Alixorexton Improves Cognition, Fatigue, and Disease Severity in Phase 2 Narcolepsy Type 1 Study]]>

Categories